More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

ClinicalTrials.gov ID: NCT01445691

Public ClinicalTrials.gov record NCT01445691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time. When the investigators remove the tumor from your brain, it is important that they remove all of the tumor and not remove parts of normal brain. Sometimes this can be difficult because the tumor can look like normal brain. In some brain tumors, 5-ALA can make the tumors glow red under blue light. This may make it easier for your doctor to take out all of the tumor from your brain. The purpose of this study is to: * Make sure that 5-ALA helps the doctor remove more of the tumor. * Make sure 5-ALA does not cause any side effects. If you do not want to participate in this study, your doctor(s) will still do their best to remove all of the tumor in your brain. Whether or not you join this study will not change your treatment for your brain tumor.

Study identification

NCT ID: NCT01445691
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 2
Lead sponsor: Constantinos Hadjipanayis; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Interventions

5-ALA (Gliolan) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2015 (Type not available)
Primary completion: Sep 2016 (Estimated)
Completion: Sep 2016 (Estimated)
Last update posted: May 17, 2016

2015 – 2016

United States locations

U.S. sites: 6
U.S. states: 3
U.S. cities: 4

Facility	City	State	ZIP	Site status
Emory University Hospital Midtown	Atlanta	Georgia	30308	—
Emory University Winship Cancer Institute	Atlanta	Georgia	30322	—
Emory Saint Joseph's Hospital	Atlanta	Georgia	30342	—
University of Michigan	Ann Arbor	Michigan	48109	—
Henry Ford Health System	Detroit	Michigan	48202	—
Washington University School of Medicine	St Louis	Missouri	63110	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01445691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2016 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01445691 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →